0001209191-19-039262.txt : 20190627 0001209191-19-039262.hdr.sgml : 20190627 20190627162128 ACCESSION NUMBER: 0001209191-19-039262 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190626 FILED AS OF DATE: 20190627 DATE AS OF CHANGE: 20190627 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Goldman Steven M. CENTRAL INDEX KEY: 0001568216 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38135 FILM NUMBER: 19925555 MAIL ADDRESS: STREET 1: C/O DOVA PHARMACEUTICALS, INC. STREET 2: 240 LEIGH FARM ROAD, SUITE 245 CITY: DURHAM STATE: NC ZIP: 27707 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dova Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001685071 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813858961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 240 LEIGH FARM ROAD CITY: DURHAM STATE: NC ZIP: 27707 BUSINESS PHONE: 919-806-4487 MAIL ADDRESS: STREET 1: 240 LEIGH FARM ROAD CITY: DURHAM STATE: NC ZIP: 27707 FORMER COMPANY: FORMER CONFORMED NAME: Dova Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20160919 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-26 0 0001685071 Dova Pharmaceuticals Inc. DOVA 0001568216 Goldman Steven M. C/O DOVA PHARMACEUTICALS, INC. 240 LEIGH FARM ROAD, SUITE 245 DURHAM NC 27707 1 0 0 0 Common Stock 2019-06-26 4 M 0 916 7.32 A 143446 D Common Stock 2019-06-26 4 M 0 834 9.36 A 144280 D Common Stock 5000 I By LLC Stock Option (right to buy) 7.32 2019-06-26 4 M 0 916 0.00 D 2027-05-24 Common Stock 916 10084 D Stock Option (right to buy) 9.36 2019-06-26 4 M 0 834 0.00 D 2029-04-25 Common Stock 934 8233 D These shares are held by the Steven M. Goldman Family LLC (the "LLC"), of which the Reporting Person is the Managing Member. The voting and investment decisions of the LLC are made by an independent external asset manager. The Reporting Person disclaims beneficial ownership of the shares held by the LLC except to the extent of his pecuniary interest in the LLC, if any, and the inclusion of these shares on this report shall not be deemed an admission that the Reporting Person beneficially owns the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or any other purpose. The option vests over a period of three years as follows: (i) one-third of the total shares subject to the option shall vested on May 25, 2018, and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, subject to the Reporting Person's continuous service with the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock. Vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, subject to continued service as a director though the applicable vesting date. /s/ Mark Ballantyne, Attorney-in-Fact 2019-06-27